PubMed Health⌕ Search

PubMed · 6797344

The variations in thyroid function tests compatible with clinical euthyroidism after medical and surgical treatment for Graves' disease.

Abstract

Eight widely used tests of thyroid function (clinical and biochemical) were performed simultaneously on 46 thyrotoxicosis patients who were clinically well at a standardised interval after medical or surgical treatment. The aim was to establish the range of thyroid function compatible with clinical normality. While clinical scoring systems gave broadly similar results between surgically and medically-treated patients, thyroid biochemistry showed major differences. Thus while 87% of medically-treated and 74% of surgically-treated patients were classified clinically euthyroid by the clinical indices devised by Crooks and Billewicz, the TRH test was exaggerated in 77% of the latter group but in only 13% of the former. On the other hand, half of the 26% of surgical patients with a clinical index suggesting hyperthyroidism had normal thyroid hormone levels and exaggerated TRH tests. No patient was categorised as clinically hypothyroid despite basal TSH levels as high as 21 mU/L (N : less than 5 mU/L) and T4 levels as low as 42 nmol/L (N: 70.150 nmol/L). Substitution of FT4 index for total T4 did not significantly alter the classification or ranking of patients in either treatment group. The early (20-minute) 132I uptake was normal in all but one case. We conclude that abnormal laboratory tests of thyroid function are found frequently after treatment in thyrotoxicosis patients with few or no clinical features of thyroid disturbance.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

T J Wilkin, T E Isles, A Gunn, J Crooks, J Swanson Beck. The variations in thyroid function tests compatible with clinical euthyroidism after medical and surgical treatment for Graves' disease.. https://pubmed.ncbi.nlm.nih.gov/6797344/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

[Graves' orbitopathy].

Graves' orbitopathy or thyroid associated orbitopathy is the most frequent extrathyroidal manifestation of Graves' disease with autoimmune mechanism which is still incompletely understood. The epidemiologic data provided evidence that severe, infiltrative orbitopathy is present in 3-5% of patients, and the quality of life is impaired even in individuals with mild form of this disease. The anti-TSH receptor and anti-eye muscle autoantibodies have been proved to be involved into pathomechanism of orbitopathy. The accumulation of glucose-aminoglycan and proinflammatory cytokines in retro-orbital fibroblasts are responsible for enlargement of eye muscle and the retro-orbital tissues resulting in inflammation of periorbital tissues and proptosis. Management of orbitopathy can be either medical and surgical. The medical therapy relies on the use of high dose systemic glucocorticoids or retro-orbital irradiation, either alone or in combination. Recent randomized clinical trials have confirmed that glucocorticoids are more effective in intravenous than oral use. Retro-orbital radiotherapy is an effective and safe therapy for orbitopathy and the side effects are avoidable. Somatostatin analogs are not so effective as it has been waited in previous studies. The high dose intravenous immunoglobulins and pentoxifylline therapy are favorable, however, prospective randomized trials have been not yet made. The manifestation of orbitopathy includes both unavoidable (genetic background) and avoidable (smoking, cytokine therapy, iodine exposure, radioiodine therapy) risk factors. Cigarette smoking must be given up by all patients with Graves' disease. Pentoxifylline therapy is advisable for all patients with Graves'diseases, especially for those who have genetic susceptibility to autoimmune disorders and not able to give up cigarette smoking.

Graves Disease↗

The surgical management of Graves' disease.

BACKGROUND: The historical aspects of the pathophysiology and treatment of Graves' disease are briefly discussed in this paper. MATERIALS AND METHODS: The three treatment modalities of Graves' disease are anti-thyroid drug therapy, radioactive iodine therapy, and surgery. Although the majority of patients with Graves' disease in the U.S. are treated with radioactive iodine, surgery still plays an important role when patients cannot tolerate anti-thyroid drug therapy, when medical treatment is rejected by patients, or when surgery is deemed the fastest and safest route in managing the patient. CONCLUSIONS: The indications for surgical management of Graves' disease are discussed with emphasis on available data supporting the extent of thyroid resection based on the incidences of hypothyroidism, recurrence of hyperthyroidism, recurrent laryngeal nerve injury and hypoparathyroidism.

Graves Disease↗